- Activities: HER2 Breast Cancer Tweetorial 4: HER2 Equivocal and HER2-low , Virtual Town Hall: An Overview of the FDA s Final Rule on Laboratory Tests - May 21, 2024, Virtual Pathology Grand Rounds, 16 DEI-related Annual Meeting recorded sessions, API Commentaries 2025, GYN Lab Comparison Glass 2025, 2025 Resident Question Bank (RQB), NonGYN Virtual Image Slide Set 2025, 2025 NonGYN Assessment Glass, 2025 NonGYN Digital Image Program, Lab Medicine Review 2025, AJCP Manuscript Review 2025, Inside the Lab Podcasts 2025, GYN Virtual Assessment 2025, Case Reports 2025, CheckPath Hematopathology 2025, CheckPath Clinical Pathology 2025, CheckPath Anatomic Pathology 2025, CQI Modules, 2024 Resident Question Bank (RQB), GYN25-GLASS, 2024 ASCP Annual Meeting, API Commentaries 2024, Resident Review Series: On-Demand, HER2 Breast Cancer Tweetorial: HER2-low emerges as a new classification, Patient Safety, UPI, AMP Breast Cancer Molecular Testing Catching Up to Increased Complexity, AMP 2023 Annual Meeting, AMP 2023 Horizons Series, Virtual Pathology Grand Round - Renal Pathology Made Easy: A Concise Review of Medical Renal Pathology with Board Relevant Topics Confirmation, Virtual Pathology Grand Rounds: Quality Assurance and Improvement in the Cytopathology Laboratory: Key Concepts in Laboratory Management, GYN Virtual Assessment 2023, HER2 Breast Cancer Tweetorial 5: Disparities in Care and Updates in HER2-low, HER2 Breast Cancer Tweetorial 3: HER2 Intratumoral Heterogeneity, Resectable Melanoma: Assessing Pathological Response Following Neoadjuvant Treatment, Advanced Melanoma: The Evolving Role of Biomarker Testing in Treatment and Prognosis, Resectable Non-Small Cell Lung Cancers: The Role of Biomarker Testing and Evaluation of Pathological Response Following Neoadjuvant Treatment, ABPath 2023 CertLink Program, 2024 Inside the Lab Podcasts, Grant Products, Cervical Cancer Screening Guidelines: An Update in Light of the Pending USPSTF Draft Guideline Release, Emerging Biomarkers in the Assessment of Alzheimer s Disease, Advanced NSCLC, Virtual Pathology Grand Round: A Case-Based and Brief Smattering of Practical Oral Pathology, NonGYN Virtual Image Slide Set 2024, Educating with Impact: Practical Tips for Creating Engaging Presentations, Journal CME 2024, Castleman Disease: Case-Based Microlearning, CheckPath Clinical Pathology 2024, CheckPath Anatomic Pathology 2024, Microlearning Series: Effective Test Utilization for Clinical Laboratories, TNBC and Immunotherapy: Key Applications for Pathologists, Considerations Around Establishing a PD-L1 Laboratory Developed Test (LDT), Navigating Challenges with PD-L1 Combined Positive Score (CPS), Case Reports 2023, CSOnline2024, CheckPath Hematopathology 2024, HER2 Breast Cancer Tweetorial 6: Optimizing Communication when HER2 Expression is Low, Biomarker Testing in Colorectal Cancer, 2024 NonGYN Digital Image Program, API Commentaries 2023, Diagnostic Pitfalls and Challenges in Hepatocellular Carcinoma, Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer, Preparing for a New Era: A HER2-low Breast Cancer Implementation Guide, The Science of HER2-low Breast Cancer and Implications for the Pathology Team, Death During the Pandemic, UPI, AMP 2022 Annual Meeting, AMP 2022 ROC, NonGYN Virtual Image Slide Set - 23, NonGYN Assessment 2023, Idiopathic Multicentric Castleman Disease Tweetorial, HER2 Breast Cancer Tweetorial 4: HER2 equivocal and HER2-low, 2023 NonGYN Digital Image Program, 2023 Resident Question Bank (RQB), LMU Contemporary Issue Courses 2022, 2023 Inside the Lab Podcasts, AJCP 2023, PD-L1 Testing Considerations, (Nearly) Everything You Learned About Race in Medical School is Wrong, BLOOD WARS? Talking to Your Doctors About Transfusion, The Molecular Biomarker Revolution in Metastatic NSCLC, Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer, HER2 Breast Cancer Tweetorial 2: Examining the Implications of HER2-low, Multidisciplinary approach to diagnosis and biomarker testing in gastrointestinal cancer, Online Tumor Board Simulation: Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community Practice, Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer, Advancing Health Equity: Overcoming Barriers to Immuno-Oncology in Persons of Color, HER2 Testing in Breast Cancer: Improving IHC Performance
- Provider Ship: 1
- Provider Address: Chicago, IL, USA
- Activity Link: http://www.ascp.org
- Number of Activities Reported Last Year: 170
- Name of Contact: Faye Ramsey
- Phone Number: (312) 541-4999
- Address: 33 West Monroe, Suite 1600, Chicago, IL, 60603, USA
- Accreditation Status: Accreditation with Commendation
- Accredited Provider: ACCME
- Activity Format: Enduring Material, Journal CME/CE, Live Course, Manuscript Review, Other/Blended Learning
Deprecated: File Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /nas/content/live/sleepliteracy/wp-includes/functions.php on line 6121
Leave a Reply